The Academic Approach to Biotech Stocks: Alan Leong of BioWatch News
Source: George S. Mack of The Life Sciences Report  (1/20/16)
Combining academic discipline with methodical due diligence, Alan Leong of BioWatch News undertakes a regimented review of each biotech and medtech stock he investigates. In some cases he will follow a company's clinical development program and data for years before he pulls the trigger and recommends a name. In this interview with The Life Sciences Report, Leong presents a number of names for investors' consideration. Many won't be mentioned in his usual write-ups: It's an early look at what's on his watch list and in his inbox. Each company carries its own risks, but every stock has a special growth story that could propel huge gains if data fall into place. More >

Chen Lin: Chinese Volatility Could Fuel a Lithium-Price Rocket Launch
Source: JT Long of The Energy Report  (1/19/16)
When China's stock market started cratering at the beginning of the year, veteran investor and newsletter writer Chen Lin was rubbing his hands in anticipation of the opportunities that would be opening up, particularly in lithium and natural gas. In this interview with The Energy Report, the author of What is Chen Buying? What is Chen Selling? shares his insights on what pushed battery-grade lithium prices up fourfold and which companies could benefit from a continued supply-demand imbalance. As a bonus, he also lists the three companies he thinks could take advantage of high overseas natural gas prices to actually return money to investors in the energy space. More >

Five Companies Swiss Asset Manager Florian Siegfried Is Watching
Source: JT Long of The Gold Report  (1/18/16)
When a leading Swiss bank recommended its clients sell all their gold, AgaNola Asset Manager Florian Siegfried knew the precious metal was preparing for an upswing. In this interview with The Gold Report, he shares five junior mining names that have made smart moves during the down time and are well positioned for an upswing. More >

Almaden: Succeeding in a Tough Resource Market with World-Class Management and Gold-Silver Discovery
Source: JT Long of The Gold Report  (1/13/16)
With approximately $5.5 million in the bank, a 3.5-million-ounce gold equivalent Measured and Indicated resource, zero debt and a robust, updated preliminary economic assessment, Almaden Minerals Ltd. CEO Morgan Poliquin says the company is in position to not only survive this tough market but to continue adding significant value at a deep discount. While other companies are trying to figure out how to keep the lights on, Almaden has been active. The company recently completed a spinout of a large portfolio of exploration projects and royalties—including a royalty on Ixtaca—into Almadex Minerals Inc. and purchased an option on a mint condition mill that reduced the initial capital cost estimate by some $70 million. In this interview with The Gold Report, the second-generation geologist points to the fact that 95% of the Tuligtic property, which hosts the Ixtaca Zone, remains unexplored and that the company can drill for about a third of what most operators pay. He says that the company’s market cap is less than the savings from the purchase of the mill, as an indication that a potential buyout is a plausible scenario. More >

A Bucket of Canadian Stocks Set to Soar in 2016: Euro Pacific Canada's Doug Loe
Source: Staff of The Life Sciences Report  (1/13/16)
The new year is off to a turbulent start, with indices across all markets, including biotech, sliding downward in the face of headwinds from China. Canadian healthcare stocks offer a windbreak for biotech investors, however, especially if they select a diversified basket across the various sectors. In this interview with The Life Sciences Report, Euro Pacific Canada's Doug Loe details a basket of Canadian companies that offer shelter from the storm. More >

How Does Jayant Bhandari Maximize Returns and Minimize Risk?
Source: Brian Sylvester of The Gold Report  (1/11/16)
Sometimes a market in turmoil offers opportunity. Independent investment adviser Jayant Bhandari regularly sifts through bourses to find opportunities that maximize his reward for the least amount of risk. Bhandari currently sees two paths to value: companies that were either oversold in heavy tax-loss selling late in 2015 or in the "free upside" offered in arbitrage situations. In this interview with The Gold Report, Bhandari explains why much of the world's populace is already chasing gold and why a smattering of junior gold equity names offer more than what a market in turmoil might suggest. More >

Major Medical Journal Publishes Data from BrainStorm Stem Cell Study
Source: Staff of The Life Sciences Report  (1/11/16)
There is no cure for ALS, a debilitating and ultimately fatal neurological disease. But BrainStorm Cell Therapeutics Inc.'s NurOwn stem cell platform, currently in clinical trials, solicited responses in some patients, resulting in publication of a paper in the prestigious Journal of the American Medical Association, according to a company press release. BrainStorm made the credibility-building announcement on the opening day of major biotech conferences in San Francisco. More >

Why Is Charles Gibson Nervous About the Fed's Actions?
Source: Brian Sylvester of The Gold Report  (1/7/16)
Charles Gibson, an analyst with London-based Edison Investment Research, is nervous. Gibson says the U.S. Federal Reserve's statement that it would push the benchmark interest rate to 1.375% by the end of 2016 could send the U.S. economy in the wrong direction for the sake of containing mostly nonexistent inflation. He says the economy's capacity to sustain higher interest rates—especially higher real interest rates—is limited and that could ultimately create greater safe-haven investment demand for gold. In light of some choppy economic times ahead, Gibson and his colleague Tom Hayes recommend defensive equity names with little risk in this interview with The Gold Report. More >

Immunotherapy Inside the Cell: Three Companies on Their Way to the 'Holy Grail' of Cancer Treatment
Source: Tracy Salcedo of The Life Sciences Report  (1/6/16)
Targeting diseases from inside the cell could be medicine's version of the dawn of the Internet. Or, as newsletter writer Chen Lin describes it, advances from companies like Sorrento Therapeutics Inc. to introduce autologous immunotherapy intracellularly "opens a whole dimension." Dorman Followwill of Frost & Sullivan suggests this new approach could shift the focus from "therapy" to "cure," with rewards for the companies leading the way. In this article, The Life Sciences Report explores the possibilities of these new technologies—and the prospects for companies like Sorrento, Inovio Pharmaceuticals Inc. and OncoSec Medical Inc.—with Lin, Followwill and Ram Selvaraju of Rodman and Renshaw. More >

Dundee's David Talbot Says Green Energy Trend Is Your Friend
Source: Brian Sylvester of The Energy Report  (1/5/16)
David Talbot of Dundee Capital Markets forecasts uranium demand growth of about 6% compounded annually through 2020, which ought to be more than enough to kickstart depressed U3O8 prices. Nuclear energy is part of a growing trend away from fossil fuels toward green energy and things like lithium-ion batteries for cars and energy storage. Talbot explains that lithium demand is expected to grow even faster than uranium demand, and the market is already undergoing a supply deficit. In this interview with The Energy Report, he offers his top picks in the uranium and lithium spaces, as well as a graphite name, all poised to ride the green energy trend higher. More >

Gold Standard Ventures Is Uncovering Bonanza Grades in Nevada's Carlin Trend
Source: JT Long of The Gold Report  (1/4/16)
In the wake of what has been described as "obscene" intersects at Gold Standard Ventures' newly consolidated Railroad-Pinion project and a corresponding jump in the share price, CEO Jon Awde shares with The Gold Report readers his plans for moving the project forward in 2016. More >

Veteran Investor Rick Rule Reveals a Unique Arbitrage Opportunity
Source: Karen Roche of The Gold Report  (1/4/16)
One of the hardest things for a mining executive to do may be nothing. But in a market that is not rewarding companies for pulling resources out of the ground, Sprott US Holdings Inc. CEO Rick Rule would prefer to see what he calls "optionality" rather than dilution from companies looking to justify salaries. In this interview with The Gold Report, he praises innovative precious metals streams on base metal projects and one Canadian company that is adding value and being rewarded for it. More >

A Year of Tips for Winning the Natural Resource Investment War
Source: The Energy Report Staff   (12/29/15)
Energy investors are no strangers to boom-and-bust cycles. In fact, a number of the experts interviewed by The Energy Report in 2015 took a certain amount of glee in the opportunities they knew would open up in low-price markets for oil and gas, uranium and lithium. Let's take a trip around the world as we recall the words of wisdom these experts shared, and see if they can spark a better understanding of what we can expect during the next turn around the sun. More >

2015: A Year of Investing Perspective
Source: The Gold Report Staff  (12/28/15)
As we at The Gold Report interviewed the investing stars in 2015, we saw some patterns develop. Whether it was in the wake of terror attacks, bond defaults, currencies (we are looking at you, Swiss Central Bank and China, decoupling from the euro and dollar respectively), political drama in the U.S., Iran, Turkey, Ukraine and Germany or the long-rumored Federal Reserve interest rate hike, the call seemed to be for patience. Crises come and go, cycles have their way with commodities and then move on only to return again under another headline. Smart investors, according to the experts we interviewed, know that the way to weather these storms is to be diversified. The way to profit from them is to be contrarian. Let's take a stroll down memory lane and see what it tells us about the road ahead. More >

Why CSR Makes Sense for Communities, Companies and Investors
Source: JT Long of The Gold Report  (12/24/15)
Mining companies and their shareholders have come to the realization that doing the right things in the communities where they operate is important for a lot of reasons, including the bottom line. Mining executives also tell The Gold Report that the most effective corporate social responsibility (CSR) programs are orchestrated cooperatively instead of applied prescriptively. More >

Growth by Acquisition Is Solid: Russell Stanley of Mackie Research Capital
Source: George S. Mack of The Life Sciences Report   (12/23/15)
The traditional biotech investor wants to hit the lottery with a blockbuster molecule, but there are less risky avenues to profit, where capital is deployed to leverage the healthcare market via reimbursement from Medicare, the Affordable Care Act and private-pay insurance. In this interview with The Life Sciences Report, Russell Stanley of Mackie Research Capital tells investors that growth is where you find it, including in acquisitions. Stanley offers three names that, based on his current target prices, offer investors potential returns of more than 100%. More >

Gear Up for a Violent Uranium Price Spike: Cantor Fitzgerald's Rob Chang
Source: Kevin Michael Grace of The Energy Report  (12/22/15)
The price of uranium is still in the doldrums, but that will change soon—and violently, says Rob Chang of Cantor Fitzgerald Canada. In this interview with The Energy Report, he explains that electric utilities will begin to run short of fuel even before 2020, when 33 additional reactors are expected to come on line. With that in mind, Chang predicts that prices could triple in the next few years, and highlights a half-dozen equities that will likely supply the increased demand and thereby deliver multiples to investors. More >

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Conducted by Aethlon's Exosome Sciences Subsidiary
Source: Gail Dutton of The Life Sciences Report  (12/22/15)
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (AEMD:NASDAQ), is pioneering the potential use of an exosome-based biomarker to diagnose chronic traumatic encephalopathy (CTE), a condition that otherwise can only be identified postmortem. As James "Jim" Joyce, executive chairman, tells The Life Sciences Report, other companies are exploring this approach in oncology, but Exosome Sciences is the only company advancing an exosome-based candidate to diagnose CTE. More >

Cantor Fitzgerald's Rob Chang Names Four Miners that Can Survive $1,050 Gold and $15 Silver
Source: Kevin Michael Grace of The Gold Report  (12/21/15)
The price of gold has see-sawed since the Federal Reserve raised interest rates on Dec. 16, and market experts debate if the action is good or bad for gold. Rob Chang of Cantor Fitzgerald Canada believes that after the small rate hike doomsayers are overstating their case and that gold should sell in 2016 for about $100/oz more than today. In this interview with The Gold Report, he argues that in today's climate cash costs below $1,000/oz are the bare minimum requirement for survival. Happily, Chang highlights three gold producers and one silver producer that have what it takes. More >

RestorGenex and Diffusion Pharmaceuticals Announce Merger to Form Oncology Biotech Company
Source: The Life Sciences Report Staff   (12/21/15)
The merger of RestorGenex Corp. (RESX: OTCQX) and privately held Diffusion Pharmaceuticals LLC, announced Tuesday, Dec. 15, will create an oncology-focused clinical-stage company with a diversified development portfolio of product candidates addressing novel targets, including several orphan indications, according to a press release issued by the companies. The combined company will be named Diffusion Pharmaceuticals Inc. and will be headquartered in Charlottesville, Virginia. More >

Redstar Gold's Ken Booth Discovers Formula for Success in the Alaskan Gold Fields
Source: Peter Byrne of The Gold Report  (12/17/15)
Redstar Gold Corp. has locked down a district-scale, high-grade gold property off the coast of Alaska. In an interview with The Gold Report, Redstar CEO Ken Booth reveals the secrets of the Unga Project: high-grade gold in the ground, everywhere. Redstar has a focused plan to keep drilling the mineralized property; Booth is looking to add weight to the company's sparkling roster of stockholders and institutional partners. More >

Eric Coffin Calls Out the Fed's Biggest Mistake and What You Can Do to Protect Your Portfolio
Source: Brian Sylvester of The Gold Report  (12/17/15)
Eric Coffin, editor of HRA Journal, writes one of the must-read newsletters in the junior mining sector. In this interview with The Gold Report, Coffin implores gold equity investors to ask: Is the project financeable in this market? And he discusses some companies he covers in the HRA Journal with the know-how to find funds, as well as a couple of uranium names that would benefit from utilities re-entering the market to find long-term delivery deals. But Coffin gets rolling by questioning U.S. Federal Reserve Chairman Janet Yellen's timing, warning investors about the growing divergence between equity and higher yield markets, and shooting down the accepted theory that the U.S. dollar index is heading to 120. More >

Eric Coffin Calls Out the Fed's Biggest Mistake and Gives Uranium Names That Can Boost Your Portfolio
Source: Brian Sylvester of The Gold Report  (12/17/15)
Eric Coffin, editor of HRA Journal, one of the must-read newsletters in the junior mining sector, questions Fed Chair Janet Yellen's timing, warns investors about the growing divergence between equity and higher yield market and discusses which companies are poised to profit from uranium's mined supply deficit. More >

Let Your Biotech Winners Ride into Orbit: Jason Napodano of BioNap Consulting
Source: George S. Mack of The Life Sciences Report  (12/16/15)
Before starting his own firm in July, Jason Napodano spent more than 12 years at Zacks Investment Research producing highly detailed small-cap biotechnology research. Today, as owner and senior analyst at BioNap Consulting, Napodano is doing much the same, but with more flexibility. He follows dozens of companies and continues to perform diligence on new names with the single goal of finding multibaggers. One of his themes is to take a biotech basket-of-stocks approach, since he knows some names will fail but the winners will move upward with momentum. In this interview with The Life Sciences Report, Napodano discusses small-cap names with the potential to power portfolios to extraordinary levels. More >

An Immunotherapeutic Approach to Glioblastoma: ImmunoCellular Therapeutics' CEO Andrew Gengos
Source: George S. Mack of The Life Sciences Report  (12/16/15)
Los Angeles-based ImmunoCellular Therapeutics Ltd. is on the verge of a pivotal Phase 3 trial with its dendritic cell immunotherapy for brain cancer. It's an extraordinary and exciting time for CEO Andrew Gengos, who is a veteran biotech executive. In this interview with The Life Sciences Report, Gengos discusses his firm's recently reported Phase 2 data in glioblastoma, as well as the company's strategy for the upcoming registration trial. More >